Cargando…
Targeting of interleukin-17 in the treatment of psoriasis
“Psoriasis” is a chronic immune-mediated inflammatory disorder with epidermal hyperplasia. There is some evidence that the cytokine interleukin-17A (often known as IL-17), which is mainly produced by Th17 cells, has a role in the pathogenesis of psoriasis. “IL-17” is a pro-inflammatory cytokine main...
Autores principales: | Lønnberg, Ann Sophie, Zachariae, Claus, Skov, Lone |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168861/ https://www.ncbi.nlm.nih.gov/pubmed/25246805 http://dx.doi.org/10.2147/CCID.S67534 |
Ejemplares similares
-
Off-Label Treatments for Pediatric Psoriasis: Lessons for the Clinic
por: Haulrig, Morten B, et al.
Publicado: (2021) -
Effect of Anti-interleukin-17 Treatment on Haemoglobin A1c Levels
por: SCHWARZ, Christopher Willy, et al.
Publicado: (2020) -
Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
por: Näslund-Koch, Charlotte, et al.
Publicado: (2020) -
Cohort profile: the clinical ‘Psoriasis in Adolescents’ (PIA) cohort in Denmark
por: Blegvad, Christoffer, et al.
Publicado: (2019) -
Treatment and Burden of Disease in a Cohort of Patients with Prurigo Nodularis: A Survey-based Study
por: TODBERG, Tanja, et al.
Publicado: (2020)